FBLG
FibroBiologics, Inc.
Next earnings Jul 29, 2026 · consensus $-0.73 EPS
$0.83
▲ +12.67%$0.83▼ -93.32%
over 1Y
L $0.73EODHDH $14.92
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+12.7%
1W+12.7%
1M-26.2%
3M-79.0%
YTD-82.8%
1Y-93.3%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 8 analysts
Buy
Conservative balance sheet (liabilities/equity 0.56x).
Return on equity -302.9% · latest
FibroBiologics, Inc. shows limited reported revenue, and -302.9% ROE.
Financials · annual, by fiscal year
| Line item | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$4.47M | -$8.89M | -$13.7M | -$16.6M |
| Net income | -$5.12M | -$16.5M | -$11.2M | -$18.6M |
| Diluted EPS | -$0.18 | -$0.68 | -$0.34 | -$0.42 |
| Net margin | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$51.2M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-33.4%
FCF yield-29.8%
Quality & risk
ROIC (est.)-203.7%
Free cash flow-$16.7M
Total debt$300K
Net cash$4.59M
Piotroski F-Score2/6
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+79.1%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
- 8-K Officer / director change2026-06-23
- 8-K Material agreement2026-05-06
- 8-K Officer / director change2026-05-05
- DEF 14A Proxy statement2026-05-05
- 8-K Material agreement2026-05-01
- 10-Q Quarterly report2026-04-30
- 8-K Reg FD disclosure2026-04-20
- 8-K Charter / bylaws change2026-04-17
- 8-K/A Amended 8-K2026-04-09
Recent filings
all on EDGAR ↗4Period ending 2026-06-232026-06-23open ↗4Period ending 2026-06-232026-06-23open ↗4Period ending 2026-06-232026-06-23open ↗4Period ending 2026-06-232026-06-23open ↗8-KPeriod ending 2026-06-222026-06-23open ↗8-KPeriod ending 2026-05-052026-05-06open ↗424B5Filing2026-05-06open ↗8-KPeriod ending 2026-05-042026-05-05open ↗ARSPeriod ending 2025-12-312026-05-05open ↗DEFA14AFiling2026-05-05open ↗DEF 14APeriod ending 2026-05-052026-05-05open ↗4Period ending 2026-05-042026-05-04open ↗
Frequently asked
- Is FibroBiologics, Inc. (FBLG) a buy?
- FBLG currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.56x).
- What is FibroBiologics, Inc.'s quality score?
- FBLG scores 35.46153846153846/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001958777, latest 10-Q filed 2026-04-30) · EODHD · as of 6/23/2026, 12:46:31 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.